Public Employees Retirement Association of Colorado Decreases Stock Position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Public Employees Retirement Association of Colorado trimmed its position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 3.6% in the 1st quarter, according to its most recent disclosure with the SEC. The institutional investor owned 13,875 shares of the biopharmaceutical company’s stock after selling 522 shares during the quarter. Public Employees Retirement Association of Colorado’s holdings in Alnylam Pharmaceuticals were worth $2,074,000 as of its most recent filing with the SEC.

Other hedge funds have also recently added to or reduced their stakes in the company. Allspring Global Investments Holdings LLC grew its holdings in shares of Alnylam Pharmaceuticals by 572.0% during the first quarter. Allspring Global Investments Holdings LLC now owns 168 shares of the biopharmaceutical company’s stock worth $25,000 after buying an additional 143 shares in the last quarter. Quent Capital LLC raised its holdings in Alnylam Pharmaceuticals by 246.0% in the 4th quarter. Quent Capital LLC now owns 173 shares of the biopharmaceutical company’s stock valued at $33,000 after acquiring an additional 123 shares during the last quarter. Altitude Crest Partners Inc. purchased a new position in Alnylam Pharmaceuticals in the 1st quarter worth approximately $30,000. GAMMA Investing LLC acquired a new position in shares of Alnylam Pharmaceuticals during the 4th quarter worth approximately $52,000. Finally, V Square Quantitative Management LLC purchased a new stake in shares of Alnylam Pharmaceuticals in the fourth quarter valued at approximately $52,000. 92.97% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Alnylam Pharmaceuticals

In related news, CEO Yvonne Greenstreet sold 8,301 shares of the business’s stock in a transaction that occurred on Tuesday, June 25th. The stock was sold at an average price of $230.99, for a total value of $1,917,447.99. Following the completion of the sale, the chief executive officer now directly owns 80,534 shares in the company, valued at approximately $18,602,548.66. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. In other Alnylam Pharmaceuticals news, Director Amy W. Schulman sold 21,700 shares of the company’s stock in a transaction dated Wednesday, May 29th. The shares were sold at an average price of $148.60, for a total transaction of $3,224,620.00. Following the completion of the sale, the director now directly owns 8,436 shares in the company, valued at $1,253,589.60. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Yvonne Greenstreet sold 8,301 shares of the stock in a transaction that occurred on Tuesday, June 25th. The shares were sold at an average price of $230.99, for a total value of $1,917,447.99. Following the sale, the chief executive officer now owns 80,534 shares of the company’s stock, valued at approximately $18,602,548.66. The disclosure for this sale can be found here. In the last quarter, insiders sold 74,450 shares of company stock worth $15,287,984. 1.50% of the stock is owned by corporate insiders.

Alnylam Pharmaceuticals Stock Up 0.6 %

Shares of ALNY opened at $236.28 on Tuesday. The firm’s 50 day moving average price is $200.71 and its 200 day moving average price is $172.70. Alnylam Pharmaceuticals, Inc. has a twelve month low of $141.98 and a twelve month high of $263.73.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its quarterly earnings data on Thursday, May 2nd. The biopharmaceutical company reported ($0.52) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.75) by $0.23. The business had revenue of $494.33 million during the quarter, compared to analyst estimates of $428.01 million. The firm’s revenue for the quarter was up 54.8% on a year-over-year basis. During the same period in the previous year, the firm posted ($1.40) EPS. As a group, equities analysts forecast that Alnylam Pharmaceuticals, Inc. will post -3.99 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts have weighed in on the company. HC Wainwright reissued a “buy” rating and set a $400.00 price objective on shares of Alnylam Pharmaceuticals in a research note on Monday, June 24th. Royal Bank of Canada raised their price target on shares of Alnylam Pharmaceuticals from $235.00 to $250.00 and gave the stock an “outperform” rating in a report on Tuesday, June 25th. JPMorgan Chase & Co. lifted their price target on shares of Alnylam Pharmaceuticals from $160.00 to $248.00 and gave the company a “neutral” rating in a research report on Wednesday, July 3rd. William Blair reissued an “outperform” rating on shares of Alnylam Pharmaceuticals in a research report on Monday, April 8th. Finally, UBS Group lifted their target price on Alnylam Pharmaceuticals from $253.00 to $288.00 and gave the company a “buy” rating in a report on Friday, June 28th. Eight investment analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $256.73.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.